Fidson Healthcare Wins Roche-Backed Licence to Manufacture Generic Influenza Drug for 129 Countries
Fidson Healthcare Plc, a Nigerian pharmaceutical manufacturer, has been selected by the Medicines Patent Pool (MPP) to produce generic versions of Roche’s baloxavir marboxil.
In Brief
- •Fidson Healthcare Plc, a Nigerian pharmaceutical manufacturer, has been selected by the Medicines Patent Pool (MPP) to produce generic versions of Roche’s baloxavir marboxil.
- •The selection places Fidson among 11 manufacturers from Brazil, China, India, Indonesia, Malaysia, Uganda, Ukraine, and Vietnam.
- •The agreement covers nearly all low- and middle-income countries, subject to regulatory approval, potentially expanding access to influenza treatment.
Why It Matters
The selection of Fidson Healthcare as a manufacturer of generic baloxavir marboxil is significant for several reasons. Firstly, it strengthens the global supply chain for influenza treatment, ensuring that more countries can access the drug. Secondly, it diversifies the manufacturing base, which is crucial for preparedness during future health emergencies. Lastly, it positions Nigeria as a key player in the international pharmaceutical supply network, potentially boosting the country's economic and technological capabilities in the healthcare sector.
Key Details
- Number of Selected Manufacturers
- 11
- Number of Eligible Countries
- 129
- Drug Name
- Baloxavir marboxil
- Licensing Agreement Date
- May 2026
Context & Background
The Medicines Patent Pool (MPP) and Roche have previously signed a voluntary licensing agreement to facilitate the development and production of generic versions of baloxavir marboxil. This agreement aims to ensure that life-saving medicines are accessible to people in low- and middle-income countries.
Original Reporting & Sources
VNews is an independent briefing product. Original reporting remains credited to the following publishers:
This brief was synthesized automatically using attributed third-party reporting. VNews is a digital news publication produced under the VContent Group brand and operated by Francis Vincent Sunday in Ghana, independent from the publishers cited above. Read our AI Transparency Policy and Editorial & Corrections Policy.